Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020
March 11 2020 - 8:25AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that it will release financial results for the
fourth quarter and year-end 2019 after the market closes on
Wednesday, March 25, 2020. Ron Rocca, President and Chief Executive
Officer, and Kamal Adawi, Chief Financial Officer, will host a
conference call to review the Company’s results at 4:30 PM Eastern
Time (1:30 PM Pacific Time).
Interested parties may access the conference call by dialing
(877) 407-3982 (U.S.) or (201) 493-6780 (international).
Participants wishing to access the call via webcast should
use the link posted on the Exagen investor relations website at
https://investors.exagen.com/.
A replay of the conference call will be available until
Wednesday, April 1, 2020 at 11:59 PM Eastern Time (8:59 PM Pacific
Time). Interested parties may access the replay of the conference
call by dialing (844) 512-2921 (U.S.) or (412) 317-6671
(international) using passcode 13699461. Additionally, a
recording of the webcast will be available using the link on the
Exagen investor relations website 30 minutes after the call
concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
Investors
Westwicke Partners Mike CavanaughMike.Cavanaugh@westwicke.com
646.677.1838
Company Contact
Exagen Inc. Kamal Adawi, Chief Financial
OfficerKAdawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024